89 related articles for article (PubMed ID: 37150731)
1. [Tertiary lymphoid structures in cancer: From biology to therapeutic guides].
Quesada S; Lebreton C; Caux C; Italiano A; Dubois B
Bull Cancer; 2023 Jun; 110(6):657-664. PubMed ID: 37150731
[TBL] [Abstract][Full Text] [Related]
2. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures.
Omotesho QA; Escamilla A; Pérez-Ruiz E; Frecha CA; Rueda-Domínguez A; Barragán I
Front Immunol; 2024; 15():1348156. PubMed ID: 38333212
[TBL] [Abstract][Full Text] [Related]
4. T follicular helper cells in cancer, tertiary lymphoid structures, and beyond.
Cui C; Craft J; Joshi NS
Semin Immunol; 2023 Sep; 69():101797. PubMed ID: 37343412
[TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of tertiary lymphoid structures by chemoimmunotherapy in bladder cancer.
Zhang L; Zhang R; Jin D; Zhang T; Shahatiaili A; Zang J; Wang L; Pu Y; Zhuang G; Chen H; Fan J
Br J Cancer; 2024 Apr; 130(7):1221-1231. PubMed ID: 38332180
[TBL] [Abstract][Full Text] [Related]
6. Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Petroni G; Pillozzi S; Antonuzzo L
Cancer Res; 2024 Apr; 84(8):1199-1209. PubMed ID: 38381540
[TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.
Byers C; Gill M; Kurtansky NR; Alessi-Fox C; Harman M; Cordova M; Gonzalez S; Guitera P; Rotemberg V; Marghoob A; Chen CJ; Dy J; Kose K; Rajadhyaksha M; Sahu A
Front Med (Lausanne); 2022; 9():981074. PubMed ID: 36388913
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications.
Wang S; Wang H; Li C; Liu B; He S; Tu C
MedComm (2020); 2024 Mar; 5(3):e489. PubMed ID: 38469550
[TBL] [Abstract][Full Text] [Related]
9. Machine Learning-Based Characterization and Identification of Tertiary Lymphoid Structures Using Spatial Transcriptomics Data.
Li S; Wang Z; Huang HD; Lee TY
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612697
[TBL] [Abstract][Full Text] [Related]
10. Rapid Generation of hPSC-Derived High Endothelial Venule Organoids with In Vivo Ectopic Lymphoid Tissue Capabilities.
Wang X; Li X; Zhao J; Li Y; Shin SR; Ligresti G; Ng AHM; Bromberg JS; Church G; Lemos DR; Abdi R
Adv Mater; 2024 Apr; 36(15):e2308760. PubMed ID: 38306610
[TBL] [Abstract][Full Text] [Related]
11. Tertiary Lymphoid Structures Validated as Biomarker.
Cancer Discov; 2024 Jan; 14(1):OF2. PubMed ID: 37991371
[TBL] [Abstract][Full Text] [Related]
12. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response.
Chen Z; Wang X; Jin Z; Li B; Jiang D; Wang Y; Jiang M; Zhang D; Yuan P; Zhao Y; Feng F; Lin Y; Jiang L; Wang C; Meng W; Ye W; Wang J; Qiu W; Liu H; Huang D; Hou Y; Wang X; Jiao Y; Ying J; Liu Z; Liu Y
NPJ Precis Oncol; 2024 Mar; 8(1):73. PubMed ID: 38519580
[TBL] [Abstract][Full Text] [Related]
13. Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy.
Wang X; Juncker-Jensen A; Huang G; Nagy ML; Lu X; Cheng L; Lu X
Cancer Commun (Lond); 2024 Apr; 44(4):499-503. PubMed ID: 37864307
[No Abstract] [Full Text] [Related]
14. Tertiary lymphoid structures and cytokines interconnections: The implication in cancer immunotherapy.
Li H; Ding JY; Zhang MJ; Yu HJ; Sun ZJ
Cancer Lett; 2023 Aug; 568():216293. PubMed ID: 37392991
[TBL] [Abstract][Full Text] [Related]
15. Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy.
Zou X; Guan C; Gao J; Shi W; Cui Y; Zhong X
Front Immunol; 2023; 14():1222719. PubMed ID: 37529035
[TBL] [Abstract][Full Text] [Related]
16. Impaired function of dendritic cells within the tumor microenvironment.
Xiao Z; Wang R; Wang X; Yang H; Dong J; He X; Yang Y; Guo J; Cui J; Zhou Z
Front Immunol; 2023; 14():1213629. PubMed ID: 37441069
[TBL] [Abstract][Full Text] [Related]
17. Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes.
Karapetyan L; AbuShukair HM; Li A; Knight A; Al Bzour AN; MacFawn IP; Thompson ZJ; Chen A; Yang X; Dadey R; Karunamurthy A; De Stefano DV; Sander C; Kunning SR; Najjar YG; Davar D; Luke JJ; Gooding W; Bruno TC; Kirkwood JM; Storkus WJ
Front Immunol; 2023; 14():1171978. PubMed ID: 37435077
[TBL] [Abstract][Full Text] [Related]
18. Germinal center-dependent and -independent immune responses of tumor-infiltrating B cells in human cancers.
Playoust E; Remark R; Vivier E; Milpied P
Cell Mol Immunol; 2023 Sep; 20(9):1040-1050. PubMed ID: 37419983
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients.
Houel A; Foloppe J; Dieu-Nosjean MC
Semin Immunol; 2023 Sep; 69():101796. PubMed ID: 37356421
[TBL] [Abstract][Full Text] [Related]
20. Single-cell transcriptome sequencing of B-cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy.
Wang Q; Sun K; Liu R; Song Y; Lv Y; Bi P; Yang F; Li S; Zhao J; Li X; Chen D; Mei J; Yang R; Chen K; Liu D; Tang S
Clin Transl Med; 2023 Aug; 13(8):e1346. PubMed ID: 37525587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
